Value
7.1/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 4.2 |
| Analyst target | 9.0 |
- ▸Attractively valued
EDIT · Why this verdict
Why Editas Medicine (EDIT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
EDIT shows strong overbought momentum with clean engine gates and a solid recent earnings-beat record, but severe cash burn and a sharply declining revenue base keep quality metrics below the platform floor.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Momentum is very strong (RSI 86, score 7.7) with the stock trading above its 200-day MA, and the engine's momentum and asymmetry gates both pass cleanly. Engine gate (passed) | Momentum should remain elevated and the asymmetry ratio should hold above 1.5 as the technical strength persists over the next several months. | →Stable |
| CounterRSI 86 is deep into overbought territory, historically prone to a sharp mean-reversion pullback especially in small-cap biotech names. | ||
The company is burning cash at an extreme rate relative to revenue (FCF at -191% of revenue), with a weak 2/9 Piotroski F-Score and no identified moat. Quality breakdown | FCF as a percentage of revenue should improve toward -100% or better as the clinical pipeline matures or cost controls take hold. | →Stable |
| CounterHeavy cash burn is standard for clinical-stage gene-editing biotechs investing in trial programs, and doesn't by itself indicate operational distress if the cash runway is well funded. | ||
Revenue has declined sharply (-39% YoY), reflecting a shrinking collaboration/licensing revenue base. Growth breakdown | Revenue growth should turn positive or stabilize above -10% YoY within the next four quarters. | →Stable |
| CounterCollaboration-revenue-driven biotechs often see lumpy, milestone-based revenue that can decline sharply between milestone payments without reflecting core program health. | ||
The company has beaten earnings estimates in 3 of the last 4 quarters, with an average surprise of nearly 27%, a positive execution signal. Catalyst breakdown | The beat rate should hold at 3 or more beats out of the next 4 reporting quarters. | →Stable |
| CounterEPS beats for a cash-burning, pre-revenue biotech often reflect beating a deeply negative consensus loss estimate rather than genuine operating outperformance. | ||
Momentum is very strong (RSI 86, score 7.7) with the stock trading above its 200-day MA, and the engine's momentum and asymmetry gates both pass cleanly.
→StableEngine gate (passed)
- Expectation
- Momentum should remain elevated and the asymmetry ratio should hold above 1.5 as the technical strength persists over the next several months.
CounterRSI 86 is deep into overbought territory, historically prone to a sharp mean-reversion pullback especially in small-cap biotech names.
The company is burning cash at an extreme rate relative to revenue (FCF at -191% of revenue), with a weak 2/9 Piotroski F-Score and no identified moat.
→StableQuality breakdown
- Expectation
- FCF as a percentage of revenue should improve toward -100% or better as the clinical pipeline matures or cost controls take hold.
CounterHeavy cash burn is standard for clinical-stage gene-editing biotechs investing in trial programs, and doesn't by itself indicate operational distress if the cash runway is well funded.
Revenue has declined sharply (-39% YoY), reflecting a shrinking collaboration/licensing revenue base.
→StableGrowth breakdown
- Expectation
- Revenue growth should turn positive or stabilize above -10% YoY within the next four quarters.
CounterCollaboration-revenue-driven biotechs often see lumpy, milestone-based revenue that can decline sharply between milestone payments without reflecting core program health.
The company has beaten earnings estimates in 3 of the last 4 quarters, with an average surprise of nearly 27%, a positive execution signal.
→StableCatalyst breakdown
- Expectation
- The beat rate should hold at 3 or more beats out of the next 4 reporting quarters.
CounterEPS beats for a cash-burning, pre-revenue biotech often reflect beating a deeply negative consensus loss estimate rather than genuine operating outperformance.
Per-dimension breakdown
Quality
3.3/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 9.8 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -94% of revenue
Growth
5.0/10data confidence 50%Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.3 |
| OBV | 10.0 |
| MA position | 2.2 |
| Volume | 3.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+2.1%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.5 |
- ▸Analyst upside: 139%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Negligible insider selling — $19,092 (0.005% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.1 |
| quality rank | 0.0 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.3 |
| support resistance | 5.9 |
| 52w position | 1.2 |
| gap | 6.0 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 3.1 |
| debt equity | 9.4 |
- ▸High short interest justified: 25%
- ▸High IV: 141%
- ▸Above max pain $0
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 4 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:5.2>=4.5
- ASYMMETRY:7.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- 8K_CRITICAL:4.01
- EARNINGS_PROXIMITY:4d<=7d
Warning (1)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
7.21
Upside
+108.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 56 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -44% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the 8K_CRITICAL gate's 4.01 outcome against Insider at 7.3 and asymmetric R:R of 7.21.
The strongest dimensions are Insider at 7.3, Value at 7.1, and Sentiment at 6.8; the weakest are Risk (lower is worse) at 3.3, Quality at 3.3, and Peer rank at 4.5. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 7.21 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Overbought Momentum Clean Gates
Trip ifRSI falls below 30 within the next month.
- P2Severe Cash Burn
Trip ifFCF as a percentage of revenue stays below -150% for 2 consecutive quarters.
- P3Declining Revenue Base
Trip ifRevenue growth stays below -25% YoY for 2 consecutive quarters.
- P4Strong Recent Earnings Beats
Trip ifEarnings surprise falls below 0% in both of the next 2 reporting quarters.